TSS
CRDL

Two Sigma Securities’s Cardiol Therapeutics CRDL Stock Holding History

Two Sigma Securities’s Portfolio CRDL Stock Details CRDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-20,673
Closed -$22.1K – 1559
2025
Q3 		$22.1K Buy
+20,673
New +$25.1K ﹤0.01% 1121
2024
Q4 		– Sell
-16,916
Closed -$33.5K – 1950
2024
Q3 		$33.5K Buy
+16,916
New +$35.1K ﹤0.01% 2422
2024
Q2 		– Sell
-14,681
Closed -$26.6K – 3083
2024
Q1 		$26.6K Buy
+14,681
New +$19.8K ﹤0.01% 2643
2023
Q3 		– Sell
-13,359
Closed -$11.9K – 3014
2023
Q2 		$11.9K Buy
+13,359
New +$8.82K ﹤0.01% 2570
2023
Q1 		– Sell
-33,564
Closed -$17.1K – 2757
2022
Q4 		$17.1K Buy
+33,564
New +$20.5K ﹤0.01% 2289
2022
Q1 		– Sell
-11,280
Closed -$21K – 2166
2021
Q4 		$21K Buy
+11,280
New +$31.2K ﹤0.01% 1401

Other funds holding CRDL

TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Two Sigma Securities's CRDL Position: Q4 2025 in Review

Two Sigma Securities sold out of Cardiol Therapeutics (CRDL) in Q4 2025, closing a stake of 20,673 shares — an estimated $22.1K sold.

Two Sigma Securities first reported a position in CRDL in Q4 2021 and held it in 6 quarters. The position peaked at $33.5K in Q3 2024. 41 funds tracked by Wall St. Rank hold CRDL as of Q4 2025.

  • Two Sigma Securities reported no remaining Cardiol Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Two Sigma Securities sold 20,673 Cardiol Therapeutics shares in Q4 2025, an estimated $22.1K.
  • Two Sigma Securities first reported a position in Cardiol Therapeutics in Q4 2021 and held it in 6 quarters.
  • Two Sigma Securities's Cardiol Therapeutics position peaked at $33.5K in Q3 2024.
  • 41 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q4 2025.

Based on Two Sigma Securities's 13F filing for Q4 2025, filed 17 Feb 2026.